147 related articles for article (PubMed ID: 24481944)
1. Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission.
Chu SC; Wang TF; Su YC; Kao RH; Wu YF; Li DK; Li SC; Li CC; Wells DA; Loken MR
Int J Hematol; 2014 Mar; 99(3):296-304. PubMed ID: 24481944
[TBL] [Abstract][Full Text] [Related]
2. Analysis of hematogones in bone marrow from acute myeloid leukaemia cases posttherapy.
Zheng J; Du W; Yao J; You Y; Li W; He Y; Li X; Liu W; Wu Y; Hu Y; Jin R; Zou P; Huang S; Hu Y; Zhang M
Eur J Clin Invest; 2013 Nov; 43(11):1140-6. PubMed ID: 23992300
[TBL] [Abstract][Full Text] [Related]
3. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
4. Hematogones: a new prognostic factor for acute myeloblastic leukemia.
Chantepie SP; Salaün V; Parienti JJ; Truquet F; Macro M; Cheze S; Vilque JP; Reman O
Blood; 2011 Jan; 117(4):1315-8. PubMed ID: 21079153
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of hematogones in patients with acute myeloid leukemia.
Chantepie SP; Parienti JJ; Salaun V; Benabed K; Cheze S; Gac AC; Johnson-Ansah H; Macro M; Damaj G; Vilque JP; Reman O
Am J Hematol; 2016 Jun; 91(6):566-70. PubMed ID: 26934680
[TBL] [Abstract][Full Text] [Related]
6. An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia.
Martínez A; San Miguel JF; Vidriales MB; Ciudad J; Caballero MD; López-Berges MC; Moro MJ; Calmuntia MJ; Ortega F; Orfao A
Cytometry; 1999 Apr; 38(2):70-5. PubMed ID: 10323219
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
[TBL] [Abstract][Full Text] [Related]
8. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
9. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
10. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease.
Liao H; Zheng Q; Jin Y; Chozom T; Zhu Y; Liu L; Jiang N
Sci Rep; 2019 Dec; 9(1):19722. PubMed ID: 31871314
[TBL] [Abstract][Full Text] [Related]
12. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
[TBL] [Abstract][Full Text] [Related]
14. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
15. Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group.
Keino D; Kinoshita A; Tomizawa D; Takahashi H; Ida K; Kurosawa H; Koike K; Ota S; Iwasaki N; Fujimura J; Yuza Y; Kiyotani C; Yamamoto S; Osumi T; Ueda T; Mochizuki S; Isoyama K; Hanada R; Tawa A; Manabe A; Toguchi Y; Ohara A
Int J Hematol; 2016 Apr; 103(4):416-22. PubMed ID: 26781613
[TBL] [Abstract][Full Text] [Related]
16. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
18. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
[TBL] [Abstract][Full Text] [Related]
19. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
[TBL] [Abstract][Full Text] [Related]
20. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
